Efficacy and Safety of Tetravalent Dengue Vaccines in Children and Adolescents: A Systematic Review of Phase 3 Randomized Controlled Trials

Authors

  • Nidianti Nerissa Author
  • Nana Sri Rahayu Universitas Prima Nusantara Bukittinggi Author
  • Sri Mardlaniah Universitas Prima Nusantara Bukittinggi Author

DOI:

https://doi.org/10.35730/1g8ywk15

Keywords:

Dengue, vaccine, children, systematic review, randomized controlled trial

Abstract

Background: Dengue is a major mosquito-borne disease in tropical countries, including Indonesia. Tetravalent dengue vaccines have been tested in large phase 3 randomized controlled trials (RCTs). This systematic review summarizes their efficacy and safety in children and adolescents.

Methods: Peer-reviewed phase 3 placebo-controlled RCTs of tetravalent dengue vaccines in children and adolescents, reporting virologically confirmed dengue, were eligible. Data were extracted and synthesized without meta-analysis, following the SWiM reporting guideline, with qualitative risk-of-bias appraisal using RoB 2 domains. Tables summarize eligibility (Table 1), trial characteristics (Table 2), serotype-specific efficacy (Table 3), TIDES follow-up (Table 4), and key findings (Table 5).

Findings: Three RCTs (CYD14, CYD15, TIDES; 51,243 randomized participants) were included. Vaccine efficacy against virologically confirmed dengue was 56.5% (95% CI 43.8–66.4) in CYD14, 60.8% (95% CI 52.0–68.0) in CYD15, and 80.2% (95% CI 73.3–85.3) in TIDES. Efficacy against hospitalized dengue was 80.3% in CYD15 and 95.4% (95% CI 88.4–98.2) in TIDES. Efficacy varied by serotype in CYD15. In published follow-up of TIDES, efficacy against symptomatic dengue was 61.2% at 54 months. Serious adverse events were similar between vaccine and placebo groups where reported.

Conclusion: Tetravalent dengue vaccines reduce symptomatic and hospitalized dengue in children and adolescents in endemic settings, with efficacy varying by vaccine, serotype, and population.

Downloads

Published

2026-09-30